Login Register Cart 0
Review Article

Pomic和Glycomic标记从COPDrote中区分肺腺癌

卷 27, 期 20, 2020

页: [3302 - 3313] 页: 12

弟呕挨: 10.2174/0929867325666181017112939

价格: $65

摘要

肺腺癌是全世界癌症患者死亡的主要原因之一，慢性阻塞性肺病(COPD)在死亡统计中也很高。此外，慢性阻塞性肺疾病(COPD)患者发展为原发性肺癌的风险很高。预防、风险评估和非侵入性诊断对降低COPD和肺癌死亡率至关重要。因此，需要更好、更准确的分子诊断标志物(biomarkers)对这些肺部疾病进行早期鉴别诊断，以帮助临床医生做出更好的治疗决定。这篇综述集中在最近发现的腺癌和COPD在蛋白质组和糖蛋白水平上的生物标志物。第一部分是对蛋白质标记的总结，第二部分是对多糖标记的研究。它们用于区分慢性炎症(COPD)和恶性(腺癌)疾病的详细讨论。

关键词: 肺癌，肺腺癌，COPD，分子标记，蛋白质组学，糖组学。

« Previous Next »
[1]
Cancer Research UK Lung cancer mortality statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/mortality (January 3, 2014).
[2]
Sholl, L.M. Biomarkers in lung adenocarcinoma: a decade of progress. Arch. Pathol. Lab. Med., 2015, 139(4), 469-480.
[http://dx.doi.org/10.5858/arpa.2014-0128-RA] [PMID: 25255293]
[3]
Bittner, N.; Ostoros, G.; Géczi, L. New treatment options for lung adenocarcinoma--in view of molecular background. Pathol. Oncol. Res., 2014, 20(1), 11-25.
[http://dx.doi.org/10.1007/s12253-013-9719-9] [PMID: 24306880]
[4]
Mo Ahn, J.; Yoel Cho, J. Current serum lung cancer biomarkers. J. Mol. Bio. Diag, 2013, s4, 1
[5]
American Cancer Society https://www.cancer.org/ cancer/lung-cancer.html (2016)
[6]
Lu, A.; Zhang, L. Tumor-dependent and -independent serum/plasma biomarkers for early diagnosis of lung cancer. Transl. Med. (Sunnyvale), 2016, 06(01)1000160
[http://dx.doi.org/10.4172/2161-1025.1000160]
[7]
Ostoros, G. In Korányi Bulletin; National Korányi Pulmonology Institute: Budapest, 2018, Vol. 1, pp. 30-38.http://www.koranyi.hu/tartalom/bulletin/Evkonyv2018.pdf
[8]
Zamay, T.N.; Zamay, G.S.; Kolovskaya, O.S.; Zukov, R.A.; Petrova, M.M.; Gargaun, A.; Berezovski, M.V.; Kichkailo, A.S. Current and prospective protein biomarkers of lung cancer. Cancers (Basel), 2017, 9(11), 155.
[http://dx.doi.org/10.3390/cancers9110155] [PMID: 29137182]
[9]
Shoshan-Barmatz, V.; Bishitz, Y.; Paul, A.; Krelin, Y.; Nakdimon, I.; Peled, N.; Lavon, A.; Rudoy-Zilberman, E.; Refaely, Y. A molecular signature of lung cancer: potential biomarkers for adenocarcinoma and squamous cell carcinoma. Oncotarget, 2017, 8(62), 105492-105509.
[http://dx.doi.org/10.18632/oncotarget.22298] [PMID: 29285267]
[10]
Postmus, P.E.; Kerr, K.M.; Oudkerk, M.; Senan, S.; Waller, D.A.; Vansteenkiste, J.; Escriu, C.; Peters, S.; Committee, E.G. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol, 2017, 28(suppl_4), iv1-iv21.
[11]
Smith, J.J.; Berg, C.D. Lung cancer screening: promise and pitfalls. Semin. Oncol. Nurs., 2008, 24(1), 9-15.
[http://dx.doi.org/10.1016/j.soncn.2007.11.007] [PMID: 18222147]
[12]
Aberle, D.R.; Adams, A.M.; Berg, C.D.; Black, W.C.; Clapp, J.D.; Fagerstrom, R.M.; Gareen, I.F.; Gatsonis, C.; Marcus, P.M.; Sicks, J.D.; Team, N.L.S.T.R. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med., 2011, 365(5), 395-409.
[http://dx.doi.org/10.1056/NEJMoa1102873] [PMID: 21714641]
[13]
Veronesi, G.; Maisonneuve, P.; Bellomi, M.; Rampinelli, C.; Durli, I.; Bertolotti, R.; Spaggiari, L. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann. Intern. Med., 2012, 157(11), 776-784.
[http://dx.doi.org/10.7326/0003-4819-157-11-201212040-00005] [PMID: 23208167]
[14]
Bigbee, W.L.; Gopalakrishnan, V.; Weissfeld, J.L.; Wilson, D.O.; Dacic, S.; Lokshin, A.E.; Siegfried, J.M. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J. Thorac. Oncol., 2012, 7(4), 698-708.
[http://dx.doi.org/10.1097/JTO.0b013e31824ab6b0] [PMID: 22425918]
[15]
Rennard, S.I.; Drummond, M.B. Early chronic obstructive pulmonary disease: definition, assessment, and prevention. Lancet, 2015, 385(9979), 1778-1788.
[http://dx.doi.org/10.1016/S0140-6736(15)60647-X] [PMID: 25943942]
[16]
Buist, A.S.; McBurnie, M.A.; Vollmer, W.M.; Gillespie, S.; Burney, P.; Mannino, D.M.; Menezes, A.M.; Sullivan, S.D.; Lee, T.A.; Weiss, K.B.; Jensen, R.L.; Marks, G.B.; Gulsvik, A.; Nizankowska-Mogilnicka, E.; Group, B.C.R. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet, 2007, 370(9589), 741-750.
[http://dx.doi.org/10.1016/S0140-6736(07)61377-4] [PMID: 17765523]
[17]
Ferré, A.; Fuhrman, C.; Zureik, M.; Chouaid, C.; Vergnenègre, A.; Huchon, G.; Delmas, M.C.; Roche, N. Chronic bronchitis in the general population: influence of age, gender and socio-economic conditions. Respir. Med., 2012, 106(3), 467-471.
[http://dx.doi.org/10.1016/j.rmed.2011.12.002] [PMID: 22197577]
[18]
Halbert, R.J.; Natoli, J.L.; Gano, A.; Badamgarav, E.; Buist, A.S.; Mannino, D.M. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J., 2006, 28(3), 523-532.
[http://dx.doi.org/10.1183/09031936.06.00124605] [PMID: 16611654]
[19]
Braido, F.; Bagnasco, D.; Scichilone, N.; Santus, P.; Solidoro, P.; Di Marco, F.; Corsico, A.; Canonica, G.W. Biomarkers in obstructive respiratory diseases: an update. Panminerva Med., 2012, 54(2), 119-127.
[PMID: 22525566]
[20]
Liu, Y.; Pleasants, R.A.; Croft, J.B.; Wheaton, A.G.; Heidari, K.; Malarcher, A.M.; Ohar, J.A.; Kraft, M.; Mannino, D.M.; Strange, C. Smoking duration, respiratory symptoms, and COPD in adults aged ≥45 years with a smoking history. Int. J. Chron. Obstruct. Pulmon. Dis., 2015, 10, 1409-1416.
[http://dx.doi.org/10.2147/COPD.S82259] [PMID: 26229460]
[21]
Houghton, A.M. Mechanistic links between COPD and lung cancer. Nat. Rev. Cancer, 2013, 13(4), 233-245.
[http://dx.doi.org/10.1038/nrc3477] [PMID: 23467302]
[22]
Raviv, S.; Hawkins, K.A.; DeCamp, M.M., Jr; Kalhan, R. Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes. Am. J. Respir. Crit. Care Med., 2011, 183(9), 1138-1146.
[http://dx.doi.org/10.1164/rccm.201008-1274CI] [PMID: 21177883]
[23]
Durham, A.L.; Adcock, I.M. The relationship between COPD and lung cancer. Lung Cancer, 2015, 90(2), 121-127.
[http://dx.doi.org/10.1016/j.lungcan.2015.08.017] [PMID: 26363803]
[24]
Indovina, P.; Marcelli, E.; Maranta, P.; Tarro, G. Lung cancer proteomics: recent advances in biomarker discovery. Int. J. Proteomics, 2011, 2011
[http://dx.doi.org/10.1155/2011/726869] [PMID: 22229091]
[25]
Pastor, M.D.; Nogal, A.; Molina-Pinelo, S.; Quintanal-Villalonga, Á.; Meléndez, R.; Ferrer, I.; Romero-Romero, B.; De Miguel, M.J.; López-Campos, J.L.; Corral, J.; García-Carboner, R.; Carnero, A.; Paz-Ares, L. IL-11 and CCL-1: Novel protein diagnostic biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid (BALF). J. Thorac. Oncol., 2016, 11(12), 2183-2192.
[http://dx.doi.org/10.1016/j.jtho.2016.07.026] [PMID: 27524264]
[26]
Bhatnagar, S.; Katare, D.P.; Jain, S.K. Serum-based protein biomarkers for detection of lung cancer. Cent. Eur. J. Biol., 2014, 9(4), 341-358.
[http://dx.doi.org/10.2478/s11535-013-0271-0]
[27]
Nalejska, E.; Mączyńska, E.; Lewandowska, M.A. Prognostic and predictive biomarkers: tools in personalized oncology. Mol. Diagn. Ther., 2014, 18(3), 273-284.
[http://dx.doi.org/10.1007/s40291-013-0077-9] [PMID: 24385403]
[28]
Chung, K.; Nishiyama, N.; Yamano, S.; Komatsu, H.; Hanada, S.; Wei, M.; Wanibuchi, H.; Suehiro, S.; Kakehashi, A. Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma. Cancer Biomark., 2012, 10(2), 101-107.
[http://dx.doi.org/10.3233/CBM-2012-0234] [PMID: 22430137]
[29]
Jin, H.; Dai, Z.N.; Jin, C.L.; Hong, J.; Ze-ning, D.; Chun-lan, J. Discrimination analysis of mass spectrometry proteomics for lung adenocarcinoma detection. Labmedicine, 2011, 42(6), 344-349.
[http://dx.doi.org/10.1309/LMXWEJV3FFDR0DHH]
[30]
Yang, L.; Che, Y.; Guo, L.; Zheng, B.; Wang, B.; Yang, Z.; Zhu, Y.; Li, J. Correlation analysis of mesenchymal-epithelial transition factor protein and human epidermal growth receptor 2 protein expression in 1479 cases of lung adenocarcinoma in China. Thorac. Cancer, 2018, 9(4), 439-444.
[http://dx.doi.org/10.1111/1759-7714.12595] [PMID: 29400000]
[31]
Li, W.; Zheng, H.; Qin, H.; Liu, G.; Ke, L.; Li, Y.; Li, N.; Zhong, X. Exploration of differentially expressed plasma proteins in patients with lung adenocarcinoma using iTRAQ-coupled 2D LC-MS/MS. Clin. Respir. J., 2018, 12(6), 2036-2045.
[http://dx.doi.org/10.1111/crj.12771] [PMID: 29363881]
[32]
Liu, Z.; Gao, Y.; Hao, F.; Lou, X.; Zhang, X.; Li, Y.; Wu, D.; Xiao, T.; Yang, L.; Li, Q.; Qiu, X.; Wang, E. Secretomes are a potential source of molecular targets for cancer therapies and indicate that APOE is a candidate biomarker for lung adenocarcinoma metastasis. Mol. Biol. Rep., 2014, 41(11), 7507-7523.
[http://dx.doi.org/10.1007/s11033-014-3641-4] [PMID: 25098600]
[33]
Almatroodi, S.A.; McDonald, C.F.; Collins, A.L.; Darby, I.A.; Pouniotis, D.S. Quantitative proteomics of bronchoalveolar lavage fluid in lung adenocarcinoma. Cancer Genomics Proteomics, 2015, 12(1), 39-48.
[PMID: 25560643]
[34]
Jiang, M.; Gu, G.; Ni, B.; Wang, W.; Shi, J.; Liao, P.; Hu, H. Detection of serum protein biomarkers by surface enhanced laser desorption/ionization in patients with adenocarcinoma of the lung. Asia Pac. J. Clin. Oncol., 2014, 10(2), e7-e12.
[http://dx.doi.org/10.1111/ajco.12057] [PMID: 23441957]
[35]
Ortea, I.; Rodríguez-Ariza, A.; Chicano-Gálvez, E.; Arenas Vacas, M.S.; Jurado Gámez, B. Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction. J. Proteomics, 2016, 138, 106-114.
[http://dx.doi.org/10.1016/j.jprot.2016.02.010] [PMID: 26917472]
[36]
Sheng, S.H.; Zhu, H.L. Proteomic analysis of pleural effusion from lung adenocarcinoma patients by shotgun strategy. Clin. Transl. Oncol., 2014, 16(2), 153-157.
[http://dx.doi.org/10.1007/s12094-013-1054-9] [PMID: 23907289]
[37]
Vykoukal, J.; Sun, N.; Aguilar-Bonavides, C.; Katayama, H.; Tanaka, I.; Fahrmann, J.F.; Capello, M.; Fujimoto, J.; Aguilar, M.; Wistuba, I.I.; Taguchi, A.; Ostrin, E.J.; Hanash, S.M. Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. Oncotarget, 2017, 8(56), 95466-95480.
[http://dx.doi.org/10.18632/oncotarget.20748] [PMID: 29221141]
[38]
Zhou, X.; Xue, L.; Hao, L.; Liu, S.; Zhou, F.; Xiong, H.; Qi, X.; Lin, D.; Shao, S. Proteomics-based identification of tumor relevant proteins in lung adenocarcinoma. Biomed. Pharmacother., 2013, 67(7), 621-627.
[http://dx.doi.org/10.1016/j.biopha.2013.06.005] [PMID: 23916545]
[39]
Lai, T.W.; Wu, D.; Chen, M.; Cao, C.; Jing, Z.L.; Huang, L.; Lv, Y.Y.; Zhao, X.N.; Lv, Q.C.; Wang, Y.J.; Li, D.M.; Wu, B.; Shen, H.H. YKL-40 expression in chronic obstructive pulmonary disease: relation to acute exacerbations and airway remodeling; Resp Res, 2016, p. 17.
[40]
Minas, M.; Mystridou, P.; Georgoulias, P.; Pournaras, S.; Kostikas, K.; Gourgoulianis, K.I. Fetuin-A is associated with disease severity and exacerbation frequency in patients with COPD. COPD, 2013, 10(1), 28-34.
[http://dx.doi.org/10.3109/15412555.2012.727922] [PMID: 23272665]
[41]
Johansson, S.L.; Roberts, N.B.; Schlosser, A.; Andersen, C.B.; Carlsen, J.; Wulf-Johansson, H.; Sækmose, S.G.; Titlestad, I.L.; Tornoe, I.; Miller, B.; Tal-Singer, R.; Holmskov, U.; Vestbo, J.; Sorensen, G.L. Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease. Respir. Med., 2014, 108(9), 1336-1344.
[http://dx.doi.org/10.1016/j.rmed.2014.06.003] [PMID: 25022422]
[42]
Merali, S.; Barrero, C.A.; Bowler, R.P.; Chen, D.E.; Criner, G.; Braverman, A.; Litwin, S.; Yeung, A.; Kelsen, S.G. Analysis of the plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling. COPD, 2014, 11(2), 177-189.
[http://dx.doi.org/10.3109/15412555.2013.831063] [PMID: 24111704]
[43]
Vagulienė, N.; Žemaitis, M.; Miliauskas, S.; Urbonienė, D.; Šitkauskienė, B.; Sakalauskas, R. Comparison of C-reactive protein levels in patients with lung cancer and chronic obstructive pulmonary disease. Medicina (Kaunas), 2011, 47(8), 421-427.
[http://dx.doi.org/10.3390/medicina47080059] [PMID: 22123552]
[44]
Balla, M.M.S.; Desai, S.; Purwar, P.; Kumar, A.; Bhandarkar, P.; Shejul, Y.K.; Pramesh, C.S.; Laskar, S.; Pandey, B.N. Differential diagnosis of lung cancer, its metastasis and chronic obstructive pulmonary disease based on serum Vegf, Il-8 and MMP-9. Sci. Rep., 2016, 6, 36065.
[http://dx.doi.org/10.1038/srep36065] [PMID: 27811960]
[45]
Sin, D.D.; Tammemagi, C.M.; Lam, S.; Barnett, M.J.; Duan, X.; Tam, A.; Auman, H.; Feng, Z.; Goodman, G.E.; Hanash, S.; Taguchi, A. Pro-surfactant protein B as a biomarker for lung cancer prediction. J. Clin. Oncol., 2013, 31(36), 4536-4543.
[http://dx.doi.org/10.1200/JCO.2013.50.6105] [PMID: 24248694]
[46]
Chu, Y.; Lai, Y.H.; Lee, M.C.; Yeh, Y.J.; Wu, Y.K.; Tsao, W.; Huang, C.Y.; Wu, S. Calsyntenin-1, clusterin and neutrophil gelatinase-associated lipocalin are candidate serological biomarkers for lung adenocarcinoma. Oncotarget, 2017, 8(64), 107964-107976.
[http://dx.doi.org/10.18632/oncotarget.22438] [PMID: 29296216]
[47]
Li, X.; Che, K.; Wang, L.; Zhang, T.; Wang, G.; Pang, Z.; Shen, H.; Du, J. Subcellular localization of β-arrestin1 and its prognostic value in lung adenocarcinoma. Medicine (Baltimore), 2017, 96(45) e8450
[http://dx.doi.org/10.1097/MD.0000000000008450] [PMID: 29137031]
[48]
Li, Y.; Cao, Z.Y.; Sun, B.; Wang, G.Y.; Fu, Z.; Liu, Y.M.; Kong, Q.F.; Wang, J.H.; Zhang, Y.; Xu, X.Y.; Li, H.L. Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol. Ther., 2011, 12(7), 610-616.
[http://dx.doi.org/10.4161/cbt.12.7.16302] [PMID: 21785272]
[49]
Hokka, D.; Maniwa, Y.; Tane, S.; Nishio, W.; Yoshimura, M.; Okita, Y.; Ohbayashi, C.; Sakai, Y.; Chen, X.; Hayashi, Y. Psf3 is a prognostic biomarker in lung adenocarcinoma. Lung Cancer, 2013, 79(1), 77-82.
[http://dx.doi.org/10.1016/j.lungcan.2012.10.001] [PMID: 23127337]
[50]
Takada, K.; Okamoto, T.; Shoji, F.; Shimokawa, M.; Akamine, T.; Takamori, S.; Katsura, M.; Suzuki, Y.; Fujishita, T.; Toyokawa, G.; Morodomi, Y.; Okano, S.; Oda, Y.; Maehara, Y. Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J. Thorac. Oncol., 2016, 11(11), 1879-1890.
[http://dx.doi.org/10.1016/j.jtho.2016.06.006] [PMID: 27346415]
[51]
Wiedl, T.; Arni, S.; Roschitzki, B.; Grossmann, J.; Collaud, S.; Soltermann, A.; Hillinger, S.; Aebersold, R.; Weder, W. Activity-based proteomics: identification of ABHD11 and ESD activities as potential biomarkers for human lung adenocarcinoma. J. Proteomics, 2011, 74(10), 1884-1894.
[http://dx.doi.org/10.1016/j.jprot.2011.04.030] [PMID: 21596165]
[52]
Zhou, W.; Ma, H.; Deng, G.; Tang, L.; Lu, J.; Chen, X. Clinical significance and biological function of fucosyltransferase 2 in lung adenocarcinoma. Oncotarget, 2017, 8(57), 97246-97259.
[http://dx.doi.org/10.18632/oncotarget.21896] [PMID: 29228607]
[53]
Ju, C.R.; Liu, W.; Chen, R.C. Serum surfactant protein D: biomarker of chronic obstructive pulmonary disease. Dis. Markers, 2012, 32(5), 281-287.
[http://dx.doi.org/10.1155/2012/509063] [PMID: 22674408]
[54]
Jaswal, S.; Saini, V.; Kaur, J.; Gupta, S. Evaluation of circulating protein biomarkers of inflammation in COPD. J. Med. Sci. Clin. Res., 2017, 5(04), 20202-20206.
[http://dx.doi.org/10.18535/jmscr/v5i4.75]
[55]
Xia, J.; Zhao, J.; Shang, J.; Li, M.; Zeng, Z.; Zhao, J.; Wang, J.; Xu, Y.; Xie, J. Increased IL-33 expression in chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell. Mol. Physiol., 2015, 308(7), L619-L627.
[http://dx.doi.org/10.1152/ajplung.00305.2014] [PMID: 25595648]
[56]
Silva, D.R.; Gazzana, M.B.; Knorst, M.M. C-reactive protein levels in stable COPD patients: a case-control study. Int. J. Chron. Obstruct. Pulmon. Dis., 2015, 10, 1719-1725.
[http://dx.doi.org/10.2147/COPD.S87015] [PMID: 26357470]
[57]
Kurt, O.K.; Tosun, M.; Kurt, E.B.; Talay, F. Pentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary disease. Inflammation, 2015, 38(1), 89-93.
[http://dx.doi.org/10.1007/s10753-014-0010-3] [PMID: 25303877]
[58]
El-Deek, S.E.; Makhlouf, H.A.; Saleem, T.H.; Mandour, M.A.; Mohamed, N.A.; Surfactant Protein, D. Surfactant protein D, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease. Med. Princ. Pract., 2013, 22(5), 469-474.
[http://dx.doi.org/10.1159/000349934] [PMID: 23860258]
[59]
Lee, K.Y.; Chuang, H.C.; Chen, T.T.; Liu, W.T.; Su, C.L.; Feng, P.H.; Chiang, L.L.; Bien, M.Y.; Ho, S.C. Proteoglycan 4 is a diagnostic biomarker for COPD. Int. J. Chron. Obstruct. Pulmon. Dis., 2015, 10, 1999-2007.
[PMID: 26451097]
[60]
Zhang, M.; Zhang, J.; Zhang, Q.; Yang, X.; Shan, H.; Ming, Z.; Chen, H.; Liu, Y.; Yin, J.; Li, Y. D-dimer as a potential biomarker for the progression of COPD. Clin. Chim. Acta, 2016, 455, 55-59.
[http://dx.doi.org/10.1016/j.cca.2016.01.024] [PMID: 26826394]
[61]
Pastor, M.D.; Nogal, A.; Molina-Pinelo, S.; Meléndez, R.; Salinas, A.; González De la Peña, M.; Martín-Juan, J.; Corral, J.; García-Carbonero, R.; Carnero, A.; Paz-Ares, L. Identification of proteomic signatures associated with lung cancer and COPD. J. Proteomics, 2013, 89, 227-237.
[http://dx.doi.org/10.1016/j.jprot.2013.04.037] [PMID: 23665002]
[62]
Varki, A.; Cummings, R.; Esko, J.; Freeze, H.; Stanley, P.; Bertozzi, C.; Hart, G.W.; Etzler, M. Essentials of Glycobiology, 2nd ed; Cold Spring Harbor Laboratory Press: Plainview, NY, 2009.
[63]
Lemjabbar-Alaoui, H.; McKinney, A.; Yang, Y.W.; Tran, V.M.; Phillips, J.J. Glycosylation alterations in lung and brain cancer. Adv. Cancer Res., 2015, 126, 305-344.
[http://dx.doi.org/10.1016/bs.acr.2014.11.007] [PMID: 25727152]
[64]
Arnold, J.N.; Saldova, R.; Galligan, M.C.; Murphy, T.B.; Mimura-Kimura, Y.; Telford, J.E.; Godwin, A.K.; Rudd, P.M. Novel glycan biomarkers for the detection of lung cancer. J. Proteome Res., 2011, 10(4), 1755-1764.
[http://dx.doi.org/10.1021/pr101034t] [PMID: 21214223]
[65]
Bartling, B.; Vanhooren, V.; Dewaele, S.; Libert, C.; Hofmann, H.S.; Haerting, J.; Nuding, S.; Silber, R.E.; Simm, A.; Chen, C.C. Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma. Cancer Biomark., 2011-2012-2012, 10(3-4), 145-154.,
[http://dx.doi.org/10.3233/CBM-2012-0239] [PMID: 22674300]
[66]
Ruhaak, L.R.; Nguyen, U.T.; Stroble, C.; Taylor, S.L.; Taguchi, A.; Hanash, S.M.; Lebrilla, C.B.; Kim, K.; Miyamoto, S. Enrichment strategies in glycomics-based lung cancer biomarker development. Proteomics Clin. Appl., 2013, 7(9-10), 664-676.
[http://dx.doi.org/10.1002/prca.201200131] [PMID: 23640812]
[67]
Liang, Y.; Ma, T.; Thakur, A.; Yu, H.; Gao, L.; Shi, P.; Li, X.; Ren, H.; Jia, L.; Zhang, S.; Li, Z.; Chen, M. Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer. Glycobiology, 2015, 25(3), 331-340.
[http://dx.doi.org/10.1093/glycob/cwu115] [PMID: 25347993]
[68]
Ruhaak, L.R.; Taylor, S.L.; Stroble, C.; Nguyen, U.T.; Parker, E.A.; Song, T.; Lebrilla, C.B.; Rom, W.N.; Pass, H.; Kim, K.; Kelly, K.; Miyamoto, S. Differential N-glycosylation patterns in lung adenocarcinoma tissue. J. Proteome Res., 2015, 14(11), 4538-4549.
[http://dx.doi.org/10.1021/acs.jproteome.5b00255] [PMID: 26322380]
[69]
Wang, X.; Deng, Z.; Huang, C.; Zhu, T.; Lou, J.; Wang, L.; Li, Y. Differential N-glycan patterns identified in lung adenocarcinoma by N-glycan profiling of formalin-fixed paraffin-embedded (FFPE) tissue sections. J. Proteomics, 2018, 172, 1-10.
[http://dx.doi.org/10.1016/j.jprot.2017.11.010] [PMID: 29157724]
[70]
Gao, C.; Taniguchi, N. Sugar Chains: Decoding the Functions of Glycans; Suzuki, T.; Ohtsubo, K.; Taniguchi, N; Japan, S., Ed.; Tokyo, 2015, pp. 259-266.
[http://dx.doi.org/10.1007/978-4-431-55381-6_16]
[71]
Angata, T.; Fujinawa, R.; Kurimoto, A.; Nakajima, K.; Kato, M.; Takamatsu, S.; Korekane, H.; Gao, C.X.; Ohtsubo, K.; Kitazume, S.; Taniguchi, N. Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases. Ann. N. Y. Acad. Sci., 2012, 1253, 159-169.
[http://dx.doi.org/10.1111/j.1749-6632.2012.06469.x] [PMID: 22380786]
[72]
Ito, E.; Oka, R.; Ishii, T.; Korekane, H.; Kurimoto, A.; Kizuka, Y.; Kitazume, S.; Ariki, S.; Takahashi, M.; Kuroki, Y.; Kida, K.; Taniguchi, N. Fucosylated surfactant protein-D is a biomarker candidate for the development of chronic obstructive pulmonary disease. J. Proteomics, , 2015, 127(Pt B), 386-394.,
[http://dx.doi.org/10.1016/j.jprot.2015.07.011]
[73]
Váradi, C.; Mittermayr, S.; Szekrényes, Á.; Kádas, J.; Takacs, L.; Kurucz, I.; Guttman, A. Analysis of haptoglobin N-glycome alterations in inflammatory and malignant lung diseases by capillary electrophoresis. Electrophoresis, 2013, 34(16), 2287-2294.
[http://dx.doi.org/10.1002/elps.201300041] [PMID: 23580236]

Rights & Permissions Print Cite
Article Metrics
24
© 2024 Bentham Science Publishers | Privacy Policy